WB result of Invivo Anti-Mouse 4-1BB (CD137) Recombinant mAb
Primary antibody: Invivo Anti-Mouse 4-1BB (CD137) Recombinant mAb at 1/1000 dilution
Lane 1: CD137 Protein, Human 2 µg
Lane 2: CD137 Protein, Rat 2 µg
Lane 3: CD137 Protein, Mouse 2 µg
Secondary antibody: Goat Anti-rat IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 27 kDa
Observed MW: 25-35 kDa
Invivo anti-mouse 4-1BB (CD137) Recombinant mAb
Invivo anti-mouse 4-1BB (CD137) Recombinant mAb
Price:
Regular price
$175 USD
Regular price
Sale price
$175 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | 4-1BB (CD137) |
| Synonyms | Tumor necrosis factor receptor superfamily member 9; 4-1BB ligand receptor; T-cell antigen 4-1BB; Ila; Ly63; Tnfrsf9 |
| Location | Cell membrane |
| Accession | P20334 |
| Clone Number | S-3800 |
| Antibody Type | Rat mAb |
| Isotype | Rat IgG1,k |
| Application | ELISA, WB, in vivo 4-1BB stimulation, in vitro 4-1BB stimulation |
| Reactivity | Ms |
| Purification | Protein G |
| Concentration | 5 mg/ml |
| Purity | >95%(Determined by SDS-PAGE) |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Dilution
| application | dilution | species |
| WB | 1:1000-1:5000 | Ms |
Background
4-1BB (CD137, TNFRSF9) is a 39 kDa inducible costimulatory receptor expressed on activated T, NK, NKT and dendritic cells that, upon engagement by its trimeric ligand 4-1BBL or agonistic antibodies, recruits TRAF1/2 to trigger NF-κB, MAPK and PI3K–Akt signaling cascades, thereby enhancing proliferation, survival, cytokine production and cytotoxicity of CD8⁺ and CD4⁺ T cells and NK cells; its expression is tightly regulated (peaking 24–72 h post-activation and restrained by PD-1/CTLA-4 pathways) and its therapeutic agonism is exploited in immuno-oncology to overcome tumor-induced exhaustion, while antagonists are explored for autoimmune diseases.
Picture
Picture
Western Blot
